Russian Journal of OncologyRussian Journal of OncologyРоссийский онкологический журнал1028-99842412-9119Eco-Vector4028410.18821/1028-9984-2015-21-1-18-25ArticlesСтатьиResearch ArticleModern possibilities of individualization of drug therapy for breast cancerСовременные возможности индивидуализации лекарственной терапии рака молочной железыPerevodchikovaN. IПереводчиковаН. ИSteninaMarina B.СтенинаМарина Борисовна

MD, PhD, DSc leading researcher Department of clinical pharmacology and chemotherapy of the Research Institute of Clinical Oncology

доктор медицинских наук, ведущий научный сотрудник отделения клинической фармакологии и химиотерапии НИИ клинической онкологии

mstenina@mail.ruN.N. Blokhin Russian Cancer Research CenterФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России15042016211-2VOL 21, NO1-2 (2016)ТОМ 21, №1-2 (2016)182522072020Copyright ©; 2016, Eco-VectorCopyright ©; 2016, ООО "Эко-Вектор"2016Eco-VectorООО "Эко-Вектор"https://rjonco.com/1028-9984/article/view/40284

N the article there are considered outputs of the 14th St Gallen International Breast Cancer Conference 2015, on the possibilities of improving the management of early breast cancer (BC) as well as the last most important results of clinical trials with antitumor drugs in advanced BC.

В работе рассмотрены основные итоги конференции по раннему раку молочной железы (РМЖ) 2015 г. (Санкт-Галленский консенсус), а также последние наиболее значимые результаты изучения противоопухолевых препаратов при диссеминированном РМЖ.

breast cancerindividualization of drug therapybreast cancer subtypesinhibitors of estrogen receptorsinhibitors of estrogen receptors inhibitors of progesterone receptorsaromatase inhibitorspalbociclibdenosumabanti-HER2 preparationsTrastuzumabPertuzumabTrastuzumab emtansineрак молочной железыиндивидуализация лекарственной терапииподтипы рака молочной железыблокаторы рецепторов эстрогеновингибиторы ароматазыпалбоциклибденосумабанти-HER2 препаратытрастузумабпертузумабтрастузумаб-эмтанзинPerou C.M., Sorlie T., Eisen M.B. et al. Molecular portraits of human breast cancer. Tumors Nature. 200; 406: 747-52.Sorlie T., Perou C.M., Tibshirani R. et al. Gene expression patterns of breast carcinoma distinguist tumor subclasses with clinical inplications. Proc. Natl. Acad. Sci. USA. 2001; 98: 10 569-74.Sorlie T., Tibshirani R., Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA. 2003; 100: 8418-23.Sortiriou C, Neo S.Y., Mc Shane L.M. et al. Breast cancer classification and prognosis based on gene expression profiles from population based study. Proc. Natl. Acad. Sci. USA. 2003; 100: 10 393-8.Perou C.M., Molecular stratification of triple negative breast cancer. Oncologist. 2011; 16 (Suppl. 1): 61-70.Prat A., Parker J.S., Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12: R68.Wigelt B., Mackay A., A’Hern R. et al. Breast cancer molecular profiling with single sample predictors. Lancet Oncol. 2010; 11: 339-49.Coates A.S., Winer E.P., Goldhirsh A et al. Tailoring therapiesimproving the management of early breast cancer. St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann. Oncol. Adv. Access published May 4 2015/ http://anonc.oxfordjournal.orgGoldhirsh A., Wood W.C., Coates A.S et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 2011; 22: 1736-47.Жукова Л.Г. Рак молочной железы с тройным негативным фенотипом у российской популяции больных. Клинико-морфологические особенности. Вопросы онкологии. 2015; 2: 189-94.Lehmann R.D., Bauer L.A., Chen I et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011: 121: 2750-67.Lehmann B.D., Pietenpol J.A., Tan A.R. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Clin. Cancer Res. 2013; 35: е31-9.Masuda H., Baggerly K.A., Wang Y. et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin. Cancer Res. 2013; 19: 5533-40.Gucalp A., Tolaney S.M., Isakoff S. et al. Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). J. Clin. Oncol. 2012; 30 (Suppl.): Abstr. 1006.Traina T.A., Miller K., Yardley D.A. et al. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). J. Clin. Oncol. 2015; 33 (Suppl): ASCO Abstr. 1003.Parker J.S., Peterson A.C., Tudor I.C. et al. A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC. J. Clin. Oncol. 2015; 33 (15, Suppl.): 1083.O’Sullivan C.C., Bradbury I., Campbell C. Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤ 2 cm: A meta-analysis of the randomized trastuzumab trials. J. Clin. Oncol. 2015; 33 (24): 2600-8.Семиглазов В.Ф., Палтуев Р.М., Семиглазов В.В. и др. Общие рекомендации по лечению раннего рака молочной железы St Gallen 2015, адаптированные экспертами Российского общества онкомаммологов. Опухоли женской репродуктивной системы. 2015; 15 (3): 43-60.Chan A., Delaloge S., Holmes F.A. et al. Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). J. Clin. Oncol. 2015; 33 (Suppl.): ASCO Abstr. 508.Swain S., Kim S., Cortes J. et al. Final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab and docetaxel in pts with HER2-positive metastatic breast cancer. ESMO. 2014; 3500_PR.Blackwell K.L., Miles D., Gianni L. et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab and a taxane. J. Clin. Oncol. 2012; 30 (Suppl.): Abstr. LBA1.Verma S., Miles D., Gianni L. et al. Trastuzumab emtansine for her2-positive advanced breast cancer. N. Engl. J. Med. 2012; 367 (19): 1783-91.Ellis P.A., Barrios C.H., Eiermann W., Toi M., Im Y.H., Conte P.F. et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. J. Clin. Oncol. 2015; 33 (Suppl.): Abstr. 507.Pagani O., Regan M.M., Walley B.A., Fleming G.F. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 2014; 371 (2): 107-18.Francis P.A., Regan M.M., Fleming G.F. et al. adjuvant ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 2015; 372: 436-46.Finn R.S., Crown J.P., Lang I. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first line treatment of oestrogen receptorpositive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015; 16: 25-35.Turner N.C., Ro J., Andre F. et al. Palbociclib in hormonereceptor-positive advanced breast cancer. DOI: 1056/NEJMoa1505270.Gnant M., Pfeiler G., Dubsky P.C. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo controlled trial. www.thelancet. com. Published online June 1, 2015 http://dx.doi.org/10.1016/S0140-6736(15)60995-3.